Idiopathic Hypersomnia

Jazz Pharmaceuticals to Present Data at SLEEP 2026 Highlighting Effects of Xywav for Narcolepsy and Idiopathic Hypersomnia
Idiopathic Hypersomnia Narcolepsy Pharmacological

Jazz Pharmaceuticals to Present Data at SLEEP 2026 Highlighting Effects of Xywav for Narcolepsy and Idiopathic Hypersomnia

Jazz Pharmaceuticals announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz’s continued focus on advancing treatment for rare and difficult-to-treat sleep […]

Idiopathic Hypersomnia Pharmacological

Avadel’s LUMRYZ Receives FDA Orphan Drug Designation for Idiopathic Hypersomnia

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hypothesis that LUMRYZ may […]

xywave jazz narcolepsy cataplexy eds
Pharmacological Idiopathic Hypersomnia

Jazz Presents Phase 3 Results of Xywav in Adults with Idiopathic Hypersomnia

Jazz Pharmaceuticals plc has announced positive results from the Phase 3 study of XywavTM (calcium, magnesium, potassium, and sodium oxybates) oral solution in adult patients with idiopathic hypersomnia, which will be presented during the Clinical Trials Plenary Session of the 2021 American Academy of Neurology (AAN) Annual Meeting. The presentation will further […]